Novartis mulls Alcon sale as it reports 4th-qtr income and sales that miss analysts' expectations

25 January 2017

Swiss pharma giant Novartis (NOVN: VX) saw its shares edge 2.3% higher to 71.15 Swiss francs, despite posting disappointing fourth-quarter and full-year 2016 financial results, as it also talked of divesting its ailing eye care business and announced a $5 billion share buy-back program.

Group sales for the quarter were down 2% at $12.32 billion, short of the average forecast of $12.5 billion, while core net income was unchanged at $2.66 billion, but missing the $2.72 billion expected on average by analysts polled by Reuters. Earnings per share fell 2% to $1.12.

For the full year, sales hit $49.41 billion, down 2%, with net income at $11.31 billion, a decline of 6%. EPS was down 5% at $4.75

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK